- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02468609
Diagnostic Value of Ultralow-dose Computed Tomography for the Detection of Pulmonary Nodules and Lung Parenchym Alterations Compared to Standard-dose CT (RADFL)
January 26, 2016 updated by: Michael Messerli, Cantonal Hospital of St. Gallen
To investigate the diagnostic value of ultralow-dose computed tomography in the detection of pulmonary nodules and lung parenchym alterations (e.g.
emphysema) compared to standard-dose-CT.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
500
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michael A Messerli, MD
- Phone Number: 0041 71 494 66 66
- Email: Michael.Messerli@kssg.ch
Study Locations
-
-
-
St. Gallen, Switzerland, 9007
- Recruiting
- Klinik fur Radiologie und Nuklearmedizin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- planned normal dose-CT by clinical indication at our institution
- obtained informed consent
Exclusion Criteria:
- planned lowdose-CT by clinical indication at institution
- no informed consent obtained
- age < 18 years
- pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Ultralow-Dose-CT
Additional Ultralow-Dose-CT of the chest
|
Patients undergoing thoracic normal dose-CT with undergo an additional Ultralow-Dose-CT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of pulmonary Nodules detected in the Ultralow-Dose thoracic CT
Time Frame: Participants CT-scan will be read out on an average date of 6 weeks after the scan
|
Difference in nodule detectability in Ultralow-Dose-CT compared to Standard-Dose-CT measured using McNemar test
|
Participants CT-scan will be read out on an average date of 6 weeks after the scan
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Patients BMI (Body mass index)
Time Frame: Measures assessed at time of read-out on an average date of 6 weeks after the scan
|
Measures assessed at time of read-out on an average date of 6 weeks after the scan
|
Patients Nodule size (mm)
Time Frame: Measures assessed at time of read-out on an average date of 6 weeks after the scan
|
Measures assessed at time of read-out on an average date of 6 weeks after the scan
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2015
Primary Completion (Anticipated)
December 1, 2016
Study Completion (Anticipated)
December 1, 2016
Study Registration Dates
First Submitted
January 30, 2015
First Submitted That Met QC Criteria
June 8, 2015
First Posted (Estimate)
June 11, 2015
Study Record Updates
Last Update Posted (Estimate)
January 27, 2016
Last Update Submitted That Met QC Criteria
January 26, 2016
Last Verified
January 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EKSG 15/007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Emphysema
-
Pulmonx CorporationRecruitingEmphysema or COPD | Emphysema, PulmonarySpain, Germany, Italy, Australia
-
Beijing Municipal Science & Technology CommissionUnknownCombined Pulmonary Fibrosis and EmphysemaChina
-
Asan Medical CenterUnknownPulmonary Disease, Chronic Obstructive | Microbiota | Emphysema or COPDKorea, Republic of
-
Aarhus University HospitalRecruitingChronic Obstructive Pulmonary Disease | Emphysema or COPDDenmark
-
Heidelberg UniversityUnknown
-
Royal Brompton & Harefield NHS Foundation TrustCompletedHeterogeneous EmphysemaUnited Kingdom
-
Aeris TherapeuticsCompleted
-
Pulmonx CorporationCompleted
-
Hospices Civils de LyonUnknownEmphysema | Pulmonary Fibrosis | Healthy Subjects | Combined Pulmonary Fibrosis and Emphysema SyndromeFrance
-
IHF GmbH - Institut für HerzinfarktforschungNot yet recruitingEmphysema or Chronic Obstructive Pulmonary DiseaseGermany
Clinical Trials on Ultralow-Dose-CT
-
University Health Network, TorontoTerminated
-
Yonsei UniversityCompletedAbdominal AbscessKorea, Republic of
-
Seoul National University HospitalCompletedLatent TuberculosisKorea, Republic of
-
Seoul National University Bundang HospitalGE Healthcare; National Research Foundation of KoreaCompletedAppendicitisKorea, Republic of
-
Kyoung Ho Lee, MDSeoul National University Bundang Hospital; Ministry of Health & Welfare, Korea and other collaboratorsCompleted
-
Jilin UniversityShanghai Zhongshan Hospital; First Affiliated Hospital Xi'an Jiaotong University and other collaboratorsNot yet recruitingCoronary Artery Disease | Chronic Kidney DiseasesChina
-
Seoul National University HospitalActive, not recruiting
-
Yale UniversityAgency for Healthcare Research and Quality (AHRQ)Completed
-
Sang-Won UmNot yet recruitingHealth Risk Behaviors
-
University Hospital, GenevaCompleted